Teva UK Ltd, a subsidiary of Teva Pharmaceutical Industries Ltd, is a leading player in the pharmaceutical industry, headquartered in Great Britain. Established in 1901, the company has evolved significantly, focusing on generic and specialty medicines that cater to a diverse range of therapeutic areas, including pain management, respiratory health, and central nervous system disorders. With a strong presence across the UK and Europe, Teva UK Ltd is renowned for its commitment to quality and innovation. The company’s extensive portfolio includes a variety of generic drugs, which are distinguished by their affordability and accessibility, making healthcare more attainable for patients. Teva's dedication to research and development has positioned it as a market leader, achieving notable milestones in the pharmaceutical sector.
How does Teva UK Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Teva UK Ltd's score of 82 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Teva UK Ltd, headquartered in Great Britain, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Teva Pharmaceutical Industries Limited, which cascades its climate commitments and targets down to Teva UK Ltd. Teva Pharmaceutical Industries Limited has set various climate initiatives, including targets aligned with the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP). However, specific reduction targets or achievements for Teva UK Ltd are not detailed in the available data. As part of its commitment to sustainability, Teva Pharmaceutical Industries Limited is actively working towards reducing its overall carbon footprint, although the specific metrics for Teva UK Ltd remain unspecified. The company is engaged in broader industry efforts to address climate change, reflecting a commitment to environmental responsibility within the pharmaceutical sector.
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 438,420,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 
| Scope 2 | 613,541,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 
| Scope 3 | - | - | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 
Teva UK Ltd's Scope 3 emissions, which decreased by 6% last year and decreased by approximately 24% since 2020, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 61% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Teva UK Ltd has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.